In situ downregulation of VLA-4 integrin cell surface expression during lymphoma growth and liver metastasis

International Journal of Oncology

Volumn 10, Issue 3, 1997, Pages 457-464

  Rocha, Marian ^a   Umansky, Victor ^a   Schirrmacher, Volker ^a   Elices, Mariano J ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b CYTEL CORPORATION   (United States)

Author keywords

ex vivo analysis; in situ downregulation; liver tumor; lymphoma metastasis; VLA 4 integrin

Indexed keywords

BETA1 INTEGRIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; LIVER METASTASIS; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031001891     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.3.457     Document Type: Article

References (35)

1. Zetter BR: Adhesion molecules in tumor metastasis. Semin Cancer Biol 4: 219-229, 1993.
2. Eliccs MJ: Leukocyte integrins. In: Integrins: Molecular and Biological Responses to the Extracellular Matrix. DA Cheresh and RP Mecham (eds.) Academic Press, San Diego, CA pp163-194, 1994.
3. Lobb RR and Hemler ME: The pathophysiologic role of α4 integrins in vivo. J Clin Invest 94: 1722-1728, 1994.
4. Mikaye K, Weissman IL, Greenberger JS and Kincade PW: Evidence for a role of the integrin VLA-4 in lymphohemopoiesis. J Exp Med 173: 559-607, 1991.
5. Bednarczyck JL and Mcintyre BW: Expression and ligand-binding function of the integrin alpha 4 beta 1 (VLA-4) on neural-crest derived tumor cell lines. Clin Exp Metastasis 10: 281-290, 1992.
6. Rosen GD, Sanes JR, LaCanee R, Cunningham JM, Roman J and Dean DC: Roles of the integrin VLA-4 and its counter receptor VCAM-1 in myogenesis. Cell 69: 1107-1119, 1992.
7. Wayner EA, Garcia-Prado A, Humphries MJ, McDonald JA and Carter WG: Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol 109: 1321-1330, 1989.
8. Guan JL and Hynes RO: Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor α4β1. Cell 60: 53-61, 1990.
9. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME and Lobb RR: VCAM-1 on activated endothelium interacts with the leucocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60: 577-584, 1990.
10. Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosso M, Osborn L, Chi-Rosso G, Newman B, Lobb R and Harlan JM: Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 76: 965-970, 1990.
11. Rice GE, Munro JW and Bevilacqua MP: Inducible cell adhesion molecule 110 (INCAM-110) is an endothelial receptor for lymphocytes: a CD11/CD18-independent adhesion mechanism. J Exp Med 171: 1369-1374, 1990.
12. Baldini LG and Cro LM: Structure and function of VLA integrins: differential expression in B-cell leukemia/lymphoma. Leuk Lymphoma 12: 197-203, 1994.
13. Freedmann AS, Saporito L, Rynhart K, Morimoto C and Nadler LM: Adhesion of follicular lymphoid germinal centers - a potential mechanism of tumor cell homing following autologous transplantation. Leuk Lymphoma 13: 47-52, 1994.
14. Van-Riet I and Van-Camp B: The involvement of adhesion molecules in the biology of multiple myeloma. Leuk Lymphoma 9: 441-452, 1993.
15. Makrynikola V, Bianchi A, Bradstock K, Gottlieb D and Hewson J: Migration of acute lymphoblastic leukemia cells into human bone marrow stroma. Leukemia 8: 1734-1743, 1994.
16. Juneja HS, Schmalsteig FC, Lee S and Chen J: Vascular cell adhesion molecule-1 and VLA-4 are obligatory adhesion proteins in the heterotypic adherence between human leukemia/lymphoma cells and marrow stromal cells. Exp Hematol 21: 444-450, 1993.
17. Schadendorf D, Gawlik C, Haney U, Ostmeier II, Suter L and Czarnetzki BM: Tumor progressive and metastatic behavior in vivo correlates with intesrin expression on melanocytic tumors. J Pathol 170: 429-434, 1993.
18. Okahara H, Yagita H, Miyake K and Okumura K: Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis. Cancer Res 54: 3233-3236, 1994.
19. Garofalo A, Chiviri RGS, Foglieni C, Pigott R, Mortarini R, Martin-Padura I, Anichini A, Gearing AI, Sanchez-Madrid F, Dejana E and Giavazzi R: Involvement of very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastasis. Cancer Res 55: 414-419, 1995.
20. Qian F, Vaux DL and Weissmann IL: Expression of the integrin α4β1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell 77: 335-347, 1994.
21. Krüger A, Schirrmacher V and von Hoegen P: Scattered micrometastases visualized at the single cell level: detection and re-isolation of lacZ labeled metastasized lymphoma cells. Int J Cancer 58: 1-10, 1994.
22. Krüger A, Umansky V, Rocha M, Hacker HJ, Schirrmacher V and von Hoegen P: Pattern and load of spontaneous liver metastasis dependent on host immune status studied with a lacZ transduced lymphoma. Blood 84: 3166-3174, 1994.
23. Larizza L, Schirrmacher V and Pflüger E: Acquisition of high metastatic capacity after in vitro fusion of a non-metastatic tumor line with a bone-marrow derived macrophage. J Exp Med 160: 1579-1584, 1984.
24. Altevogt P, Hubbe M, Ruppert M, Lohr J, von Hoegen P, Sammar M, Andrew DP, McEvoy L, Humphries MJ and Butcher EC: The α4 integrin chain is a ligand for α4β7 and α4β1. J Exp Med 182: 345-355, 1995.
25. Rocha M, Krüger A, Umansky V, von Hoegen P, Naor D and Schirrmacher V: Dynamic expression-changes in vivo of adhesion and costimulatory molecules determine load and pattern of lymphoma liver metastasis. Clin Cancer Res 2: 811-820, 1996.
26. Schirrmacher V, Beckhove P, Krüger A, Rocha M, Umansky V, Flohtner KP, Hull W, Zangemeister-Wittke U, Griesbach A, Jurianz, K and von Hoegen P: Effective immune rejection of advanced metastasized cancer. Int J Oncol 6: 506-521, 1995.
27. Miyake K, Medina K, Katsuhibo I, Kimoto M, Auerbach R and Kincade PW: A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture. J Cell Biol 114: 557-565, 1991.
28. Elices MJ, Tamraz S, Tollefson V and Volger LW: The integrin VLA-4 mediates leukocyte recruitment to skin inflammatory sites in vivo. Clin Exper Rheumatol 11: 77-80, 1993.
29. Chisholm PL, Williams CA and Lobb RR: Monoclonal antibodies to the integrin α4 subunit inhibit the murine contact hypersensitivity response. Eur J Immunol 23: 682-688, 1993.
30. Tamra S, Arrhenius T, Chiem A, Forrest MJ, Gaeta FCA, He Y, Lei J, Maewal A, Phillips ML, Volger LW and Elices MJ: Treatment of delayed-type hypersensitivity with inhibitors of the VLA-4 integrin. Springer Semin Immunopathol 16: 437-441, 1995.
31. Aihiro K, Inai K, Kuribara K, Takeda S, Kaneko M, Kuroi K and Toge T: Loss of VLA-2 collagen receptor in breast carcinoma, facilitating invasion and metastasis. Jpn J Cancer Res 84: 726-733, 1993.
32. Nigam AK, Savage FJ, Boulos PB, Stamp GW, Liu D and Pignatelli M: Loss of cell-cell and cell-matrix adhesion molecules in colorectal cancer. Br J Cancer 68: 507-514, 1993.
33. Suzuki S, Takahaski T, Nakamura S, Kolke K, Ariyoshi Y, Yakahashi T and Ueda R: Alterations of integrin expression in human lung cancer. Jpn J Cancer Res 84: 168-174, 1993.
34. Peltonen J, Larjava H, Jaakkola S, Grainick H, Akiyama SK, Yamada KM and Uitto J: Localization of integrin receptors for fibronectin, collagen, and laminin in human skin. Variable expression in basal and squamous cell carcinomas. J Clin Invest 84: 1916-1923, 1989.
35. Wang N, Butler JP and Ingber DE: Mechanotransduction across the cell surface and through the cytoskeleton. Science 260: 124-127, 1993.